Agarwal Arjun
Company insiders · Senior Vice President, Finance · Oruka Therapeutics, Inc.
- Reported transaction lines
- 10
- Buy lines
- 0
- Sell lines
- 6
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-1110
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 55417 · The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. | 2026-11-12 | 2026-11-13 | 1,458 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 67834 · The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. | 2026-11-12 | 2026-11-13 | 8,542 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 14219 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. | 2026-11-12 | 2026-11-13 | ≈ $10,700.00 100 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 14319 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $101,716.51 958 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 15277 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $720,329.87 6,842 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 22119 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $83,295.91 799 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 22918 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $82,627.64 801 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 23719 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4. | 2026-11-12 | 2026-11-13 | ≈ $50,987.90 500 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 24219 | 2026-11-12 | 2026-11-13 | 1,458 shares/units | SEC 4 |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 22761 | 2026-11-12 | 2026-11-13 | 8,542 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.